New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareGlutathione vs Survodutide

Glutathione vs Survodutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityImmune Support
Glutathione
GLP-1 / Weight Loss Agonists
Survodutide
Summary
Glutathione is the body's master endogenous antioxidant tripeptide, composed of glutamate, cysteine, and glycine. It neutralizes reactive oxygen species, supports detoxification in the liver, recycles other antioxidants (vitamins C and E), and plays a central role in immune function, DNA repair, and cellular redox balance.
Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
Half-Life
Minutes to hours depending on route; IV half-life approximately 10-30 minutes
~7 days
Admin Route
Oral (liposomal preferred), Sublingual, Intravenous, Nebulized/inhaled, Topical
SubQ
Research
Typical Dose
250-1000 mg per day
0.6 mg → 2.4 mg → 4.8 mg → 6 mg
Frequency
Once or twice daily
Once weekly
Key Benefits
  • Primary endogenous antioxidant and free radical scavenger
  • Supports hepatic detoxification of xenobiotics and heavy metals
  • Recycles vitamins C and E to maintain antioxidant network
  • Modulates immune function and T-cell activity
  • Skin brightening via inhibition of tyrosinase (IV/topical routes)
  • Neuroprotective in oxidative stress-related conditions
  • Mitochondrial protection and energy metabolism support
  • Up to 18.7% body weight reduction at 46 weeks (Phase 2)
  • Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
  • Reduces hepatic fat content via glucagon receptor-driven liver oxidation
  • Once-weekly subcutaneous injection
  • Greater weight loss potential than GLP-1 monotherapy
  • Improvements in liver fibrosis markers in early data
Side Effects
  • Oral bioavailability is limited (largely hydrolyzed in gut); liposomal or sublingual forms preferred
  • IV administration: rare allergic reactions, vein irritation
  • High-dose supplementation may cause zinc depletion over time
  • Inhaled glutathione may trigger bronchoconstriction in asthmatics
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +3 more
Stacks With